WO2012156750A1 - Vaccin contre le vih - Google Patents

Vaccin contre le vih Download PDF

Info

Publication number
WO2012156750A1
WO2012156750A1 PCT/GB2012/051124 GB2012051124W WO2012156750A1 WO 2012156750 A1 WO2012156750 A1 WO 2012156750A1 GB 2012051124 W GB2012051124 W GB 2012051124W WO 2012156750 A1 WO2012156750 A1 WO 2012156750A1
Authority
WO
WIPO (PCT)
Prior art keywords
glycoconjugate
man
unit
modified
modification
Prior art date
Application number
PCT/GB2012/051124
Other languages
English (en)
Inventor
Benjamin G DAVIS
Balakumar VIJAYAKRISHNAN
Katie DOORES
Julia KOEPPE
Original Assignee
Isis Innovation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation Limited filed Critical Isis Innovation Limited
Publication of WO2012156750A1 publication Critical patent/WO2012156750A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the invention relates to glyco conjugates and vaccine compositions and the use of
  • glycoconjugates in the prevention and treatment of HIV infection and AIDS.
  • HIV-1 is thought to have infected up to 60 million people since its discovery over 20 years ago. Of those infected, more than 20 million have died, with the vast majority of individuals affected being from developing countries. An effective vaccine is, therefore, paramount to combat the epidemic.
  • the HIV-1 envelope spike critical for viral infectivity, consists of a compact, unstable trimer of the glycoproteins gpl20 and gp41 and is a key target for design of an antibody-based HIV-1 vaccine.
  • the envelope spike undergoes rapid evolution in each individual patient, resulting in enormous sequence heterogeneity among individual isolates of HIV-1.
  • neutralization-sensitive epitopes on gpl20 and gp41 are either difficult to access or shielded from recognition by the immune system by an extensive display of host- derived N-glycans.
  • a small group of rare, broadly neutralizing antibodies (bl2, 2G12, 2F5, 4E10, Z13) against gpl20 and gp41 have been previously isolated from HIV-1- infected patients that provide protection against viral challenge in animal models as well as the more recent discovery of new highly potent human antibodies (PG9, PG16).
  • Structural analyses have revealed how they broadly neutralize HIV-1 and the mechanism by which the virus normally evades detection by the immune system. Identification of antigens that could generate similar types of broadly neutralizing antibodies is, therefore, an important step in the development of an HIV-1 vaccine. From this small group, broadly neutralizing antibody 2G12 is uniquely capable of recognizing sugars on the immunologically "silent"
  • Fig. 1 Crystallisation studies have shown that the Dl arm of the (MangGlcNAc 2 ) oligomannose (Fig. 1) is an epitope of the 2G12 antibody.
  • glycans containing the natural sugar D-mannose have previously been thought to be poor candidates for immunogens.
  • One major limitation to the recognition and, hence, immunogenicity of carbohydrate structures is their exhibition of microheterogeneity.
  • a single protein may display many variations of carbohydrate structure (glyco forms) that can result in a polyclonal and reduced antigenic response.
  • Carbohydrate-protein interactions tend also to be weaker than protein-protein interactions ( ⁇ rather that nM) further reducing affinities of antibodies to glycans.
  • glycan structures can also shield underlying peptide epitopes, thereby further reducing the effectiveness of the immunogenic response.
  • viruses typically rely on host glycosylation machinery; their glycosylation patterns are, therefore, inevitably similar to that of the host.
  • host immune mechanisms such as 2G12 should normally recognize such sugars as self and display tolerance, thus not eliciting antibodies to host derived sugars such as D-mannose.
  • the present inventors have surprisingly found that a series of modified mannose- containing glycoconjugates are capable of eliciting an immune response to the HIV-1 surface glycoprotein gpl20.
  • the present invention provides a glycoconjugate for use in treating or preventing an HIV infection or AIDS, wherein the glycoconjugate comprises an oligosaccharide group which is linked to a carrier protein, wherein the oligosaccharide group is of formula (I):
  • - M3 is a modified mannose unit
  • each M2 is the same or different and represents a mannose unit or a modified mannose
  • M l represents a mannose unit or a modified mannose unit, and the oligosaccharide moiety is linked to the carrier protein via Ml ;
  • p 0, or 1
  • q is 0 or 1 ;
  • SI is a saccharide unit or a modified saccharide unit
  • r, s and t are zero or an integer from 1 to 5, wherein at least two of r, s and t are zero; wherein the or each modified mannose unit or modified saccharide unit is a mannose unit or saccharide unit having one or more modifications, the or each modification being independently selected from modifications A and B, wherein:
  • modification A is replacement of a hydrogen atom of the mannose unit or saccharide unit with a CI -3 alkyl group optionally substituted with a hydro xyl group;
  • modification B is replacement of a hydroxyl group of the mannose unit or saccharide unit with a hydrogen atom.
  • the present invention also provides an oligosaccharide of formula (lb)
  • - Ml represents a mannose unit or a modified mannose unit, which modified
  • mannose unit is as defined above;
  • Each M2 and SI is as defined above;
  • - M3 represents a modified mannose unit having (a) modification A at one or more of the CI to C4 and C6 positions, the modified C6 position having (R) configuration, and/or (b) modification B at one or more of the C2 to C5 positions; wherein modifications A and B are as defined above.
  • the present invention provides a vaccine composition comprising
  • glycoconjugate of the invention is glycoconjugate of the invention.
  • the present invention also provides use of a glycoconjugate or
  • oligosaccharide of the invention in the manufacture of a medicament or vaccine
  • the present invention further provides a method for treating or preventing, or for ameliorating or reducing the incidence of, an HIV infection or AIDS in a subject, which method comprises administering to the subject an effective amount of a glycoconjugate of the invention.
  • Figure 1 depicts the structure of oligomannose (Man 9 GlcNAc 2 ) found on the "silent face" of gpl20. Dl, D2 and D3 arms are highlighted.
  • Figures 2a, 2b and 2c show the results of the gpl20/serum binding assay for rabbit serums 290, 304 and 379, respectively, reported in Example 16.
  • Figures 3, 4 and 5 show the results of the conjugate/serum assay reported in Example 17.
  • Figure 6 shows the results of the CFG glycan array assay reported in Example 18.
  • FIGS 7 to 9 show the results of the neutralisation assay reported in Example 19.
  • the glycoconjugate comprises a mono- or oligosaccharide linked to a carrier protein.
  • the mono- or oligosaccharide may be linked covalently to the carrier protein via a linker moiety.
  • oligosaccharide refers to a chain of linked monosaccharide units, typically a small number of monosaccharide units, e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 units, for example 2, 3, 4, 9 or 11 units linked together to form a chain.
  • the monosaccharide units are typically linked via glycosidic bonds.
  • Examples of monosaccharides include ribulose, xylulose, ribose, arabinose, xylose, lyxose, deoxyribose, psicose, fructose, sorbose, tagatose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, fucose, fuculose, rhamnose, neuramininc acid and derivatives thereof including glucosamine, N-acetylglucosamine and N-acetylneuramininc acid (sialic acic).
  • Monosaccharides having an anomeric (hemiacetal) carbon atom are typically given an a- or ⁇ - prefix, depending on the orientation of the hydroxyl group at the anomeric carbon atom.
  • Monosaccharides are typically given a D- or L- prefix, depending on the stereochemistry at the C5 position.
  • the saccharides disclosed herein may exist as isomers or mixtures of isomers, for example ⁇ / ⁇ anomers, L/D stereoisomers and ring/straight-chain isomers.
  • the present invention relates to all such isomers and mixtures of isomers of the saccharides disclosed herein, except where specified.
  • a glycosidic bond is a bond from the anomeric carbon of a monosaccharide unit (the glycosyl donor) to a glycosyl acceptor.
  • the glycosyl acceptor may be any molecule which contains a nucleophilic atom capable of forming a bond to the glycosyl donor.
  • the glycosyl acceptor is typically an oxygen atom of a hydroxyl group of the second monosaccharide unit.
  • Further examples of glycosyl acceptors include any molecule which contains a nucleophilic oxygen atom, nitrogen atom, sulfur atom or carbon atom.
  • Glycosidic bonds can be described using an arrow drawn from the glycosyl donor to the glycosyl acceptor.
  • Glu-al ⁇ 2-Man indicates a glucose unit which is linked by a glycosidic bond from its anomeric (CI) carbon, in a orientation, to the oxygen atom bound to the C2 carbon of a mannose unit.
  • CI -3 alkyl means an alkyl radical having one two or three carbon atoms.
  • a CI -3 alkyl group may be a methyl, ethyl, n-propyl or isopropyl group.
  • a CI -3 alkyl group is unsubstituted, except where specified.
  • a CI to C6 alkylene group is a linear or branched, divalent, saturated, aliphatic hydrocarbon radical containing 1 to 6 carbon atoms. Examples include methylene, ethylene and propylene
  • a C2 to C6 alkenylene group is a linear or branched, divalent, aliphatic, hydrocarbon radical containing 1 to 6 carbon atoms and one or more carbon-carbon double bond. Examples include ethenylene and propenylene.
  • a C2 to C6 alkynylene group is a linear or branched, divalent, aliphatic, hydrocarbon radical containing 1 to 6 carbon atoms and one or more carbon-carbon triple bond. Examples include ethynylene and propynylene.
  • a said alkylene, alkenylene or alkynylene group may be unsubstituted or substituted by one or more groups selected from halogen atoms and hydroyl groups.
  • a halogen atom is a fluorine, chlorine, bromine or iodine atom. Oligosaccharides
  • each mannose unit is an a-D-mannose unit
  • each modified mannose unit is an ⁇ -D-mannose unit having one or more modifications as defined in claim 1.
  • the oligosaccharide contains other monosaccharides or modified monosaccharides, these are typically also a-D-orientated.
  • the oligosaccharide contains some ⁇ -glycosidic bonds.
  • each bond from one Ml , M2, M3 or S 1 unit to another Ml , M2, M3 or S 1 unit is a glycosidic bond.
  • each bond from one Ml , M2, M3 or S 1 unit to another Ml , M2, M3 or S 1 unit is a glycosidic bond.
  • the glycosidic bond from M3 to M2 is an a-l ⁇ 2 glycosidic bond (i.e. M3-a-l ⁇ 2-M2);
  • Each glycosidic bond from one M2 to another M2 is an a-l ⁇ 2 glycosidic bond
  • the glycosidic bond from M2 to Ml is an a-l ⁇ 3 glycosidic bond (i.e.
  • each glycosidic bond from one SI to another SI is an a-l ⁇ 2 or a-l ⁇ 3 glycosidic bond (i.e. Sl-a-l ⁇ 2-Sl or Sl-a-l ⁇ 3-Sl); and/or
  • each glycosidic bond from SI to Ml or M2 is an a-l ⁇ 6 glycosidic bond (i.e. Sl-a-l ⁇ 6-Ml or Sl-a-l ⁇ 6-M2).
  • the or each modified mannose unit has one, two or three modifications, preferably one or two modifications, more preferably one modification.
  • the or each modification A in a modified mannose unit present in the glycoconjugate of the invention can be at the CI, C2, C3, C4, C5 or C6 position.
  • the or each modification A involves replacement of a hydrogen atom which is boded directly to the carbon backbone of the mannose unit.
  • the or each modification A does not involve replacement of a hydrogen atom which is part of a hydroxyl group of the mannose unit.
  • glycoconjugate of the invention is at the C3, C5 or C6 position, and more typically at the C5 position.
  • the hydrogen atom of the mannose unit is replaced with a methyl, ethyl, hydro xymethyl or hydro xyethyl group, more preferably a methyl or hydroxymethyl group, and most preferably a methyl group.
  • the or each modification B in a modified mannose unit present in the glycoconjugate of the invention can be at the C2, C3, C4, C5 or C6 position.
  • the or each modification is at the C3, C5 or C6 position of the modified mannose unit.
  • a mannose unit is modified with modification B
  • at least the C6 position of the modified mannose unit is modified with modification B.
  • only the C6 position of the modified mannose unit is modified with modification B.
  • the sum of p and q is 1 or 2.
  • the sum of p and q is 2.
  • Ml represents a mannose unit (i.e. an unmodified mannose unit).
  • M2 represents a mannose unit (i.e. an unmodified mannose unit).
  • all M2 units present in the glycoconjugate or oligosaccharide of the invention represent a mannose unit.
  • M3 represents a modified mannose unit having (a) modification A at one or more of the C3, C5 and C6 positions, and/or (b) modification B at one or more of the C3, C5 and C6 positions; preferably modification B is at the C6 position.
  • M3 contains a single modification.
  • r and s are typically zero.
  • (Sl) r , (Sl) s , or (Sl) t may represent a linear or branched oligosaccharide group.
  • r, s and t are from 0 to 5, preferably 0, 3 or 5.
  • (Sl) r , (Sl) s , and (Sl) t when present, represent a single linear or branched moiety attached to a Ml or M2 moiety.
  • (Sl) r when present, represents a single oligosaccharide group having r saccharide units, and does not represent a plurality of individual monosaccharide moieties each bonded directly to an M2 moiety.
  • each SI group may be the same or different.
  • each SI is independently a modified or unmodified mannose, unmodified galactose, unmodified fucose, sialic acid or N-acylglucosamine unit.
  • each SI is independently a modified or unmodified mannose unit.
  • SI represents a modified saccharide unit, it is modified with one or more modification A and/or modification B, as defined above. Particularly preferred modifications at SI are the same as those for the modified mannose units described above.
  • each SI is independently a mannose unit or a modified mannose unit.
  • Most preferably each SI is a mannose unit (i.e. an unmodified mannose unit).
  • (Sl) t -Ml represents group (1) or (2):
  • (Sl) t -Ml represents group (1).
  • the modified C6 position when M3 represents a modified mannose unit having modification A at the C6 position, the modified C6 position has (R) configuration. In an alternative embodiment, when M3 represents a modified mannose unit having modification A at the C6 position, the modified C6 position has (S) configuration.
  • the carrier protein is BSA or CRM;
  • Ml and/or one or more M2 is a modified mannose unit
  • one of r, s and t is an integer from 1 to 5;
  • M3 is modified at the CI, C2, C3, C4 or C5 position.
  • the oligosaccharide is of formula (la):
  • R l s R 2 , R 3 and R4 are independently a hydrogen atom or a CI -3 alkyl group optionally substituted with a hydroxyl group, and X is a hydrogen atom or a hydroxyl group, provided that X is a hydrogen atom when Ri, R 2 , R 3 and R4 all represent a hydrogen atom.
  • R l s R 2 , R 3 and R4 each independently represent a hydrogen atom, a methyl group, an ethyl group, a hydroxymethyl group or a hydroxyethyl group; preferably a hydrogen atom, a methyl group or a hydroxymethyl group; and most preferably a hydrogen atom or a methyl group.
  • R l s R 2 , R 3 and R 4 all represent a hydrogen atom, or only one of Ri, R 2 , R 3 and R 4 is other than a hydrogen atom.
  • X is a hydroxyl group.
  • R 4 is a hydrogen atom.
  • R 4 is a hydrogen atom.
  • Particularly preferred oligosaccharides for use in the treatment or prevention of an HIV infection or AIDS include:
  • glycoconjugates of the invention inlcude those containing, as the oligosaccharide:
  • the linker moiety can be any moiety capable of forming one or more covalent bonds to the oligosaccharide, and one or more covalent bonds to the carrier protein.
  • the linker moiety is a non- saccharide moiety.
  • the use of such linker moieties in glycocojugates is well known in the art.
  • the linker moieties which can be used are not particularly limited and one of skill in the art will be capable of selecting an appropriate linker.
  • Linker Factors relevant to selecting an appropriate linker include its length and chemical stability/reactivity.
  • the linker should not be so long that the oligosaccharide is too far away from the carrier protein for the glyco conjugate to be internalised by a B-cell.
  • the linker can easily be bonded to the oligosaccharide and the carrier protein in high yield, and is typically stable in an aqueous environment.
  • the linker moiety will typically be attached to the oligosaccharide moiety via the anomeric carbon atom of the Ml unit, and will typically be attached to the carrier protein via the side chain of an amino acid residue in said carrier protein, e.g. via an amine group.
  • linker moiety may be a moiety of Formula (II):
  • L and L' are independently a single bond, or a group selected from CI to C6 alkylene, C2 to C6 alkenylene and C2 to C6 alkynylene; which group may be substituted or unsubstituted by one or more (e.g. 1, 2 or 3) substituents selected from halogen atoms and hydroxyl groups; and
  • - Y is a single bond or a group selected from -NR-, -C(O)-, -C(0)-0- -O-C(O)-,
  • R and R' are independently hydrogen or a CI to C3 alkyl group
  • each L and L' are independently a single bond or a CI to C5 alkylene group.
  • L and L' taken together contain up to 8 carbon atoms, for example up to 6 carbon atoms.
  • the left hand side of L is attached to Ml and the right hand side of L' is attached to the carrier protein.
  • Y is a group -NR-C(S)-NR- -C(NR)-NR'- or -C(0)-NR-.
  • Y is - NH-C(S)-NH- -C(NH)-NH- or -C(0)-NH-.
  • carrier proteins in conjugate vaccines are well known in the art, and it will be evident to a skilled person that the carrier protein which can be used in the glycoconjugate of the present invention is not particularly limited.
  • the carrier protein used in the glycoconjugate of the present invention may be any protein capable of eliciting T-cell help in the generation of 2G 12 antibodies.
  • the carrier protein of the invention comprises or consists of a sequence which is recognized by T-cells as a hapten when presented on surface of a B-cell as a peptide:MHC complex. T- cell recognition of that peptide epitope activates the B-cell and leads to the development of an immune response against HIV-1 (i.e. the generation of antibodies which bind the gpl20 epitope).
  • Suitable carrier proteins include LTB, KLH, tetanus toxin, QP, BSA, and CRM.
  • the carrier protein in the glycoconjugate of the invention is QP, BSA, or CRM.
  • the carrier protein is CRM.
  • the carrier protein may carry more than one oligosaccharide of formula (I). Typically, the carrier protein carries from 1 to 30
  • oligosaccharides of formula (I) more typically from 1 to 20 and most typically from 1 to 15.
  • the number of oligosaccharides presented on the surface of the carrier protein is not thought to affect the strength of the oligosaccharide-2G12 interactions.
  • Step (i) involves activation of the LG group of glycosyl donor (2) and coupling with glycosyl acceptor (3) to form the tetrasaccharide-containing compound of formula (4).
  • glycosyl donors carrying a thioester-forming leaving group can be activated with N-iodosuccinimide and triflic acid.
  • Step (ii) involves deprotection of the compound of formula (4) to form the compound of formula (5).
  • the skilled person will be familiar with appropriate agents for cleaving any particular Pg.
  • 3 ⁇ 4 represents the point of attachment of the saccharide moiety to the remainder of the molecule.
  • the remainder of the molecule may be a protecting group, a protected linker moiety, or a linker moiety attached to a carrier protein.
  • the compound of formula (5) can be deprotected to form a tetrasaccharide, which can be reacted with a linker moiety and a carrier protein to give the glycoconjugate of formula (la).
  • the compound of formula (5) can be deprotected and reacted with a carrier protein to give the glycoconjugate of formula (la).
  • the compound of formula (5) is the glycoconjugate of formula (la).
  • glyconjugates of formula (I) maybe prepared according to scheme 3 :
  • ⁇ represents the point of attachment of the saccharide moiety to the remainder of the molecule.
  • the remainder of the molecule may be a protecting group, a protected linker moiety, or a linker moiety attached to a carrier protein.
  • removal of the protecting group provides an oligosaccharide of formula (lb):
  • Ml represents a mannose unit or a modified mannose unit, which modified mannose unit is as defined above;
  • Each M2 and SI is as defined above;
  • M3 represents a modified mannose unit having (a) modification A at one or more of the CI to C4 and C6 positions, the modified C6 position having (R) configuration, and/or (b) modification B at one or more of the C2 to C5 positions; wherein modifications A and B are as defined above.
  • Ml represents a mannose unit.
  • oligosaccharides of Formula (lb) are the same as for those in glycoconjugates of Formula (I), except that Ml carries a hydro xyl group at the anomeric carbon atom and is not bound to a linker moiety or a carrier protein.
  • glycoconjugates of the present invention are capable of eliciting an immune response against HIV, typically against HIV- 1.
  • the glycoconjugates When administered to a subject as part of a vaccine composition, the glycoconjugates are recognized by the B-cell antigen receptor (BCR) surface immunoglobulin, which signals to the B-cell's interior when the glycoconjugate antigen is bound and delivers the antigen to intracellular cites where it can be degraded.
  • BCR B-cell antigen receptor
  • the glycoconjugate may activate the B-cell directly.
  • peptide fragments of the carrier protein may be returned to the B-cell surface as part of a peptide:MHC complex for recognition by antigen-specific helper T-cells which make cytokines that cause the B-cell to proliferate and its progeny to differentiate into antibody-secreting cells and memory B-cells.
  • Antibodies thus secreted are capable of binding to the oligomannose glycans, typically the Dl arm, displayed on the surface of HIV envelope glycoprotein gpl20.
  • the antibody:HIV complex is recognized by Fc receptors on effector cells that bind to Fc portions provided by the antibody. Binding activates the effector cell and triggers neutralization of the HIV virus via phagocytosis and/or granule release.
  • Vaccine compositions The present invention provides a vaccine composition comprising a glycoconjugate of the invention.
  • the glycoconjugate is preferably administered together with one or more pharmaceutically acceptable carriers or diluents and optionally one or more other therapeutic ingredients.
  • the carrier (s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • carriers for injection, and the final formulation are sterile and pyrogen free. Formulation of a suitable composition can be carried out using standard pharmaceutical formulation chemistries and methodologies all of which are readily available to the reasonably skilled artisan.
  • a glycoconjugate of the invention can be combined with one or more pharmaceutically acceptable excipients or vehicles.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering substances and the like, may be present in the excipient or vehicle.
  • excipients, vehicles and auxiliary substances are generally pharmaceutical agents that do not induce an immune response in the individual receiving the composition, and which may be administered without undue toxicity.
  • Pharmaceutically acceptable excipients include, but are not limited to, liquids such as water, saline, polyethyleneglycol, hyaluronic acid, glycerol, thioglycerol and ethanol.
  • Pharmaceutically acceptable salts can also be included therein, for example, mineral acid salts such as hydrochlorides,
  • compositions may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration.
  • injectable compositions may be prepared, packaged, or sold in unit dosage form, such as in ampoules or in multi-dose containers containing a preservative.
  • Compositions include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations.
  • Such compositions may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents.
  • the active ingredient is provided in dry (e.g., a powder or granules) form for reconstitution with a suitable vehicle (e.
  • compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution.
  • This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein.
  • Such sterile injectable formulations may be prepared using a non-toxic parenterally-acceptable diluent or solvent, such as water or 1,3-butane diol, for example.
  • a non-toxic parenterally-acceptable diluent or solvent such as water or 1,3-butane diol, for example.
  • Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono-or di-glycerides.
  • compositions which are useful include those which comprise the active ingredient in micro crystalline form, in a liposomal preparation, or as a component of a biodegradable polymer systems.
  • Compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt.
  • the glycoconjugate of the invention may be encapsulated, adsorbed to, or associated with, particulate carriers.
  • suitable particulate carriers include those derived from polymethyl methacrylate polymers, as well as PLG microparticles derived from
  • poly(lactides) and poly(lactide-co-glycolides See, e.g., Jeffery et al. (1993) Pharm. Res. 10:362-368.
  • Other particulate systems and polymers can also be used, for example, polymers such as polylysine, polyarginine, polyornithine, spermine, spermidine, as well as conjugates of these molecules.
  • the compositions can be delivered to a subject in vivo using a variety of known routes and techniques.
  • the vaccine composition can be provided as an injectable solution, suspension, emulsion or dry powder and administered via parenteral, subcutaneous, epidermal, intradermal, intramuscular, intraarterial, intraperitoneal, intravenous injection using a conventional needle and syringe, or using a liquid jet injection system, or using a patch.
  • Compositions can also be administered topically to skin or mucosal tissue, such as nasally, intratracheally, intestinal, rectally or vaginally, or provided as a finely divided spray suitable for respiratory or pulmonary administration.
  • Other modes of administration include oral administration, suppositories, sublingual administration, and active or passive transdermal delivery techniques.
  • the administered compositions will comprise a suitable concentration of the glycoconjugate of the invention which is effective without causing adverse reaction.
  • concentration of the glycoconjugate in the composition will be in the range of 0.03 to 200 nmol/ml. More preferably in the range of 0.3 to 200 nmol/ml, 3 to 180 nmol/ml, 10 to 150 nmol/ml, 50 to 200nmol/ml or 30 to 120 nmol/ml.
  • the composition or formulations should have a purity of greater than 95% or 98% or a purity of at least 99%.
  • Suitable doses may be in the order of up to 15 ⁇ g, up to 20 ⁇ g, up to 25 ⁇ g, up to 30 ⁇ g, up to 50 ⁇ g, up to 100 ⁇ g, up to 500 ⁇ g or more per administration. Suitable doses may be less than 15 ⁇ g, but at least lng, or at least 2ng, or at least 5ng, or at least 50ng, or least lOOng, or at least 500ng, or at least ⁇ g, or at least 10 ⁇ g.
  • the dose used may be higher, for example, up to 1 mg, up to 2 mg, up to 3 mg, up to 4 mg, up to 5 mg or higher.
  • Such doses may be provided in a liquid formulation, at a concentration suitable to allow an appropriate volume for administration by the selected route.
  • An adjuvant may also be used in combination with the glycocojugate.
  • the adjuvant is preferably administered in an amount which is sufficient to augment the effect of the glycoconjugate or vice versa.
  • the adjuvant or other therapeutic agent may be an agent that potentiates the effects of the glycoconjugate.
  • the other agent may be an immunomodulatory molecule.
  • adjuvants include alum, monophosphoryl lipid, oligonucleotides, cholera toxin, Freund's complete or incomplete adjuvant, Ribi and QS-21.
  • the glycoconjugates are used for therapy in combination with one or more other therapeutic agents.
  • the agents may be administered separately, simultaneously or sequentially. They may be administered in the same or different compositions as the glycoconjugate. Accordingly, in a method of the invention, the subject may also be treated with a further therapeutic agent.
  • a composition may therefore be formulated with a glyco conjugate of the invention and also one or more other therapeutic molecules.
  • a vaccine composition of the invention may alternatively be used simultaneously, sequentially or separately with one or more other therapeutic compositions as part of a combined treatment.
  • Benzyl 2,4-di-O-benzyl-6-0-tert-butyldimethylsilyl-a-D-mannopyranoside 5.3.13 29 mg, 0.051 mmol
  • ethyl 2-O-acetyl-3,4,6-tri-0-benzyl-a-D-mannopyranosyl-(l ⁇ 2)- 3,4,6-tri-O- benzyl-a-D-mannopyranosyl-(l ⁇ 2)-3,4,6-tri-0-benzyl-thio-a-D-mannopyranoside 5.3.106 60 mg, 0.043 mmol
  • 2,6-di-tert-butyl-4-methylpyridine 76 mg, 0.30 mmol
  • the reagents were dissolved in DCM (1 mL) and transferred using a cannula to a flame dried flask containing 4 A molecular sieves. The mixture was stirred for 1 h and cooled to -78 °C. DCM (1 mL) was added to a flame dried flask containing 4A molecular sieves and stirred for 1 h then cooled to 0 °C. To this flask was added
  • the reagents were dissolved in DCM (1 mL) and transferred using a cannula to a flame dried flask containing 4A molecular sieves. The mixture was stirred for 1 h and cooled to -20 °C. Dimethylthiosulfonium triflate (710 of a 0.4 M solution in DCM was added to the reaction mixuture. After 1 h, t.l.c (5 : 1 , petrohethyl acetate) indicated formation of a product (R f 0.5) with complete consumption of the starting materials (R f 0.1 , 0.7). The reaction mixture was quenched with triethylamine (0.5 mL) and filtered through celite ® .
  • the reagents were dissolved in DCM (1 mL) and transferred using a cannula to a flame dried flask containing 4 A molecular sieves. The mixture was stirred for 1 h and cooled to -78 °C. Dimethylthiosulfonium triflate (69 mg, 0.27 mmoL) was added to the reaction mixuture and after 30 min the reaction mixture was allowed to warm to room temperature. After a further 1 h, t.l.c (5 : 1 , petrohethyl acetate) indicated formation of a product (R f 0.6) with complete consumption of the starting materials (R f 0.1 , 0.7).
  • Benzyl-(2,3,4,6-tetra-O-benzyl-6-5'-6-C-methyl-a-D-mannopyranosyl)-(l ⁇ 2)-3,4,6-tri-O- benzyl-a-D-mannopyranosyl-( 1 ⁇ 2)-3 ,4,6-tri-0-benzyl-a-D-mannopyranosyl-( 1 ⁇ 3)-2,4-di- O-benzyl-6-O-tert-butyldimethylsilyl-a-D-mannopyranoside 24A (96 mg, 0.049 mmol) was suspended in acetic acid (80% in water) and heated at 50°C.
  • the reagents were dissolved in DCM (1 mL) and transferred using a cannula to a flame dried flask containing 4 A molecular sieves. The mixture was stirred for 1 h and cooled to -78 °C. Dimethylthiosulfonium triflate (44 mg, 0.17 mmoL) was added to the reaction mixuture and after 30 min the reaction mixture was allowed to warm to room temperature. After a further 1 h, t.l.c (5 : 1 , petrohethyl acetate) indicated formation of a product (R f 0.6) with complete consumption of the starting materials (R f 0.1 , 0.7).
  • QP bearing alkyne at surface-exposed lysine residues was prepared by incubating a 10 mg/mL solution of QP with 25 mM of N-(4-Pentynoyloxy) succinimide (35- fold excess with respect to protein subunit) in 0.1 M potassium phosphate buffer (pH 7) with 10% DMSO for 12 hours.
  • the derivatized virus was separated from excess reagent by ultracentrifugation using a 10-40% sucrose gradient.
  • glycoconjugates of Examples 1 to 15 can be prepared by methods analogous to the foregoing Examples:
  • Example 5 ⁇ [C6-(S)-Methyl]-Man-a-(l ⁇ 2)-Man-a-(l ⁇ 2)-Man-a-(l ⁇ 3)Man ⁇ 9 -CRM
  • Example 6 ⁇ [C6-(S)-Methyl]-Man-a-(l ⁇ 2)-Man-a-(l ⁇ 2)-Man-a-(l ⁇ 3)Man ⁇ ! -QP
  • Tetrasaccharide azide 5B (Reference Example 13, 0.5 mM) was added to QP-alkyne (Reference Example 19, 1 mg/ml) in 0.1 M potassium phosphate buffer pH 7.
  • the following reagents were added sequentially: amino guanidine (AG, 5 mM), mixture of CuS0 4 :THPTA [tris(3 -hydro xypropyltrazolylmethyl)amine] in a molar ratio of 1 :5 (0.25 mM CuS0 4 , 1.25 mM THPTA), and sodium ascorbate (5 mM).
  • the reaction mixture was incubated at room temperature for 1 firs. Samples of the title compound were analyzed and purified by size- exclusion chromatography (SEC) using a Superose6 column.
  • SEC size- exclusion chromatography
  • Example 16 Enzyme Linked Immunosorbent Assays (ELISA) Four New Zealand white rabbits were immunized with a prime and three boost
  • Serum from rabbits 290, 304 and 379 show strong binding with different gpl20s and are shown in Figures 2a, 2b and 2c. Weak, medium and high binding categories in Table lb were assigned based on the serum dilution value when 50% binding was observed. The relevant serum dilution values are shown for rabbits 290, 304 and 379 in Figures 2a, 2b and 2c.
  • Results show that synthetic glycoconjugates raise antibodies which bind to the ohgomannose glycans displayed in the surface of envelope glycoprotein gpl20.
  • IgG from serum samples was tested for binding ability with carrier protein and also with the corresponding glycoconjugates.
  • the serum samples chosen for this assay were from rabbits 304 and 290. Results are shown in Figure 3.
  • serum from immunization with BSA based conjugate was tested against the natural glycoconjugate and also with the different platform based conjugates (CRM & QP).
  • serum IgG did not bind to the carrier protein and the observed binding titers were in the range of 1 : 1 ,000 ( Figure 5).
  • the serum IgG is sugar specific.
  • Binding ELISA results show that serum IgG obtained from immunization of BSA conjugates shows higher titers and is highly sugar specific.
  • QP and CRM conjugates show high sugar specific IgG titer, and also some anti-carrier properties.
  • Example 18 - CFG Glycan array Serum was probed against a wider panel of related oligomannosides on a printed glycan array. Serum was assayed at a 1 : 100 dilution to facilitate detection of lower-affinity interactions while minimizing the nonspecific background binding. Binding of serum IgG (Week 0 and Week 14) from rabbit 304 (CRM-C-5-Me-Dl) is shown in Figure 6. Week 0 bleed showed no binding to the mannose glycosides in printed array.
  • Serum antibodies from week 14 bleed of rabbit 304 shows that CRM-(C-5-Me-Dl)s elicits IgG which recognizes synthetic fragments of high-mannose oligosaccharides in Man a(l ⁇ 2)Man (glycans 205, 206, 207, 314, 313) and terminating in Man a(l ⁇ 3)Man motifs (glycans 211, 212).
  • Serum Abs did not bind the corresponding natural, high mannose glycans on a printed covalent array, only binding fragments which were linked by means of a lipid chain linker. From the glycan array list, it is also apparent that the raised antibody contains sugar specific properties.
  • Example 19 Neutralization Assay Serum from rabbit and 304 was subjected to neutralization assay using the JRCSF pseudo virus which is sensitive to monoclonal Abs such as bl2, 2G12 and 4E10 (Figure 7). The result shows that serum from rabbit 304 effectively neutralizes the virus. Based on these results similar assays were performed for this serum with different HIV-1 isolates. Neutralization assays were performed with different HIV isolates including HxB2, JRFL, JRFL NB-DBJ and Yu2. In addition to that 2G12 neutralization was also performed as a positive control. In all the cases only serum from rabbit 304 neutralizes the virus (Figure 8). The same assay was performed using pre bleed (week 0) and post bleed (week 14) and the results are shown in Figure 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un glycoconjugué destiné à être utilisé dans le traitement ou la prévention d'une infection par le VIH ou du SIDA, le glycoconjugué comprenant un groupe oligosaccharidique qui est lié à une protéine vectrice, le groupe oligosaccharidique étant de formule (I) : dans laquelle : M3 est une unité mannose modifiée ; chaque M2 est identique ou différent et représente une unité mannose ou une unité mannose modifiée ; - M1 représente une unité mannose ou une unité mannose modifiée, et la fraction oligosaccharidique est liée à la protéine vectrice via M1 ; p vaut 0, ou 1 ; q vaut 0 ou 1 ; S1 est une unité saccharidique ou une unité saccharidique modifiée ; - r, s et t sont zéro ou un nombre entier de 1 à 5, dans laquelle au moins deux de r, s et t sont zéro ; dans laquelle l'unité ou chaque unité mannose modifiée ou l'unité ou chaque unité saccharidique modifiée est une unité mannose ou une unité saccharidique ayant une ou plusieurs modifications, la modification ou chaque modification étant indépendamment choisie parmi les modifications A et B, parmi lesquelles : la modification A est le remplacement d'un atome d'hydrogène de l'unité mannose ou de l'unité saccharidique par un groupe alkyle en C1-3 facultativement substitué par un groupe hydroxyle ; et la modification B est le remplacement d'un groupe hydroxyle de l'unité mannose ou de l'unité saccharidique par un atome d'hydrogène.
PCT/GB2012/051124 2011-05-19 2012-05-18 Vaccin contre le vih WO2012156750A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1108472.0 2011-05-19
GBGB1108472.0A GB201108472D0 (en) 2011-05-19 2011-05-19 HIV vaccine

Publications (1)

Publication Number Publication Date
WO2012156750A1 true WO2012156750A1 (fr) 2012-11-22

Family

ID=44279340

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/051124 WO2012156750A1 (fr) 2011-05-19 2012-05-18 Vaccin contre le vih

Country Status (2)

Country Link
GB (1) GB201108472D0 (fr)
WO (1) WO2012156750A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105017346A (zh) * 2015-07-02 2015-11-04 中国农业大学 三六支化甘露五糖六糖对甲氧基苯基糖苷及其制备方法与应用
WO2016007765A1 (fr) 2014-07-11 2016-01-14 Gilead Sciences, Inc. Modulateurs de récepteurs de type toll pour le traitement du vih
CN108329362A (zh) * 2018-03-20 2018-07-27 江南大学 一种革兰氏阳性菌表面荚膜多糖结构衍生物的制备方法
US20210085770A1 (en) * 2019-09-23 2021-03-25 Koranex Capital Neoglycoconjugates as vaccines and therapeutic tools

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011036560A2 (fr) * 2009-09-23 2011-03-31 Novartis Ag Compositions de glycoconjugués et méthodes pour le traitement du vih

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011036560A2 (fr) * 2009-09-23 2011-03-31 Novartis Ag Compositions de glycoconjugués et méthodes pour le traitement du vih

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1991, MACK PUB. CO.
ANNA KABANOVA ET AL: "Preparation, characterization and immunogenicity of HIV-1 related high-mannose oligosaccharides-CRM197 glycoconjugates", GLYCOCONJUGATE JOURNAL, KLUWER ACADEMIC PUBLISHERS, BO, vol. 27, no. 5, 4 June 2010 (2010-06-04), pages 501 - 513, XP019818957, ISSN: 1573-4986 *
JEFFERY ET AL., PHARM. RES., vol. 10, 1993, pages 362 - 368
K. J. DOORES ET AL: "A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 40, 5 October 2010 (2010-10-05), pages 17107 - 17112, XP055032295, ISSN: 0027-8424, DOI: 10.1073/pnas.1002717107 *
NI JIAHONG ET AL: "TOWARD A CARBOHYDRATE-BASED HIV-1 VACCINE: SYNTHESIS AND IMMUNOLOGICAL STUDIES OF OLIGOMANNOSE-CONTAINING GLYCOCONJUGATES", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 17, no. 2, 1 January 2006 (2006-01-01), pages 493 - 500, XP009074356, ISSN: 1043-1802, DOI: 10.1021/BC0502816 *
VARGAS F ET AL: "Specificity analysis of antibodies formed in rabbits to a mannosyl trisaccharide: Similarity with lectin binding activity. Para-aminophenyl O- [alpha]-D-mannopyranosyl-(1->2)-[alpha]-D-mannopyranosyl-(1->6)-[alpha]-D-mannopyranoside linked to bovine serum albumin as an antigen", IMMUNOLOGICAL INVESTIGATIONS 1992 US, vol. 21, no. 7, 1992, pages 671 - 684, XP008153399, ISSN: 0882-0139 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016007765A1 (fr) 2014-07-11 2016-01-14 Gilead Sciences, Inc. Modulateurs de récepteurs de type toll pour le traitement du vih
EP4140485A1 (fr) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulateurs de récepteurs de type toll pour le traitement du vih
CN105017346A (zh) * 2015-07-02 2015-11-04 中国农业大学 三六支化甘露五糖六糖对甲氧基苯基糖苷及其制备方法与应用
CN108329362A (zh) * 2018-03-20 2018-07-27 江南大学 一种革兰氏阳性菌表面荚膜多糖结构衍生物的制备方法
US20210085770A1 (en) * 2019-09-23 2021-03-25 Koranex Capital Neoglycoconjugates as vaccines and therapeutic tools
US11925680B2 (en) * 2019-09-23 2024-03-12 Koranex Capital Neoglycoconjugates as vaccines and therapeutic tools

Also Published As

Publication number Publication date
GB201108472D0 (en) 2011-07-06

Similar Documents

Publication Publication Date Title
FI89172C (fi) Nya oligosackarider och deras anvaendning foer framstaellning av immunogener
US20030153492A1 (en) Novel glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
WO2006017180A2 (fr) Dimeres de glycopeptide et leurs utilisations
Allen et al. A second generation synthesis of the MBr1 (Globo‐H) breast tumor antigen: New application of the N‐pentenyl glycoside method for achieving complex carbohydrate protein linkages
CN106879257B (zh) 针对肺炎链球菌(Streptococcus pneumoniae)血清型8的疫苗
CN111448205B (zh) 抗肺炎克雷伯菌的疫苗
EP2560981A2 (fr) Oligosaccharides synthétiques pour un vaccin contre staphylococcus
US10206988B2 (en) Xenoantigen-displaying anti-cancer vaccines and method of making
WO2012156750A1 (fr) Vaccin contre le vih
JP2021504438A (ja) クレブシエラ ニューモニエ（Ｋｌｅｂｓｉｅｌｌａ ｐｎｅｕｍｏｎｉａｅ）に対するワクチン
US11420993B2 (en) Semi-synthetic meningococcal conjugate vaccine
KR102250099B1 (ko) 스트렙토코커스 뉴모니에 1형에 대한 합성 백신
CN108367059B (zh) 针对肺炎链球菌血清型2的合成疫苗
Wu et al. Synthesis and immunochemical studies on a Candida albicans cluster glycoconjugate vaccine
EP3016685B1 (fr) Oligosaccharides de synthèse pour vaccin contre p. aeruginosa
US20240024489A1 (en) Protected disaccharides, their process of preparation and their use in the synthesis of zwitterionic oligosaccharides, and conjugates thereof
JP7296459B2 (ja) Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する安定なワクチン
JP6622804B2 (ja) ストレプトコッカス ニューモニアエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）血清型４に対するワクチン
WO2016104647A1 (fr) Antigène vaccinal glycosylé et agent de glycosylation
CZ2002721A3 (cs) Směsi oligosacharidů, způsob jejich syntézy a syntézy disacharidu meziproduktu a derivátů disacharidu, imunogen, vakcina, makromolekuly a pouľití disacharidů a makromolekul
Langenbach Decorating Antigen with Multivalent CD22 Ligands to Prevent B-cell Mediated Anti-Drug Antibody Formation
Nikolaev et al. Synthetic glycoconjugates based on Leishmania lipophosphoglycan structures as potential anti-leishmaniasis vaccines
EP3181148A1 (fr) Vaccins contre le streptococcus pneumoniae de sérotype 2
EP3000820A1 (fr) Vaccins contre le streptococcus pneumoniae de sérotype 8
Ambre Synthesis of carbohydrate antigens of the human immunodeficiency virus-1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12723734

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12723734

Country of ref document: EP

Kind code of ref document: A1